Diabetes in Neuropsychiatric Disorders

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2010

Conditions
Schizophrenia
Interventions
DRUG

Olanzapine

16-week open trial of olanzapine. The patients were started on a dose of 15 mg/d by mouth, which could be adjusted to as low as 10 mg/d or as high as 40 mg/d, based on clinical response. The trial began while they were hospitalized and continued after discharge.

Trial Locations (1)

08036

Unitat Hospitalitzacio - Servei de Psiquiatria G096, Hospital Clinic C/Villarroel, 170, Barcelona

All Listed Sponsors
lead

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

NCT00446992 - Diabetes in Neuropsychiatric Disorders | Biotech Hunter | Biotech Hunter